MedTrace Logo

Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty

NCT04490902 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-02-24

No results posted yet for this study

Summary

Because of the immunologically privileged nature of the cornea, the graft rejection rate is less than 10% for low-risk keratoplasty. But when the cornea performed 2 or more quadrants of corneal neovascularization after ocular trauma or infection, the graft rejection rate is more than 65%, it is called high-risk keratoplasty.

This study will observe the graft survival of high-risk corneal transplantation using mixed component cornea from different donors.

Conditions

  • Corneal Transplantation

Interventions

PROCEDURE

Limbal transplantation combined with central penetrating keratoplasty

Limbal transplantation combined with central penetrating keratoplasty with single donor cornea

PROCEDURE

Limbal transplantation combined with central penetrating keratoplasty

Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea

Sponsors & Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490902 on ClinicalTrials.gov